Improving Clinical Management and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis in China via Real-world Evidence (IMPROVE Study): A Multicenter Prospective Cohort Study

被引：0

作者：

Nan Jiang ^{[1
]}

Dongzhou Liu ^{[2
]}

Xinwang Duan ^{[3
]}

Lijun Wu ^{[4
]}

Yi Liu ^{[5
]}

Hao Zhu ^{[6
]}

Yanjie Zhang ^{[7
]}

Mengtao Li ^{[8
]}

Xinping Tian ^{[9
]}

Xiaofeng Zeng ^{[10
]}

机构：

[1] Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing

[2] National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing

[3] State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing

[4] Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing

[5] Department of Rheumatology and Immunology, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, Guangdong, Shenzhen

[6] The First Affiliated Hospital, Southern University of Science and Technology, Guangdong, Shenzhen

[7] Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang

[8] Department of Rheumatology, Xinjiang Uygur Autonomous Region People’s Hospital, Xinjiang Uygur Autonomous Region, Urumuqi

[9] Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Sichuan, Chengdu

[10] Eli Lilly China, Jiangsu, Suzhou

来源：

Advances in Therapy | 2025年 / 42卷 / 6期

关键词：

Disease activity; Disease management; Improvement; Patient-reported outcomes; Rheumatoid arthritis;

D O I：

10.1007/s12325-025-03179-7

中图分类号：

学科分类号：

摘要：

Introduction: Patient-reported outcomes (PROs) help to understand rheumatoid arthritis (RA) from patients’ perspective and play an important role in RA management. This study aims to describe the PRO changes over 6 months among patients with RA in China and explore the relationships between PROs and RA disease activity. Methods: This multicenter prospective cohort study enrolled patients with RA aged ≥ 18 years. At enrollment, patients were dichotomized into remission/low disease activity (LDA) and moderate-to-high disease activity (MDA/HDA) based on Disease Activity Score-28 with C-Reactive Protein (DAS28-CRP). Only patients with MDA/HDA (DAS28-CRP ≥ 3.2) were followed for 6 months. PROs included pain, fatigue, morning stiffness, Patients’ Global Assessment (PtGA), disability, work productivity, and activity impairment. Disease activity measures included DAS28-CRP, DAS28-Erythrocyte Sedimentation Rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Results: A total of 872 patients were enrolled: 520 patients in remission/LDA and 352 in MDA/HDA. In MDA/HDA patients, pain decreased significantly from enrollment at month 1 (p < 0.0001), month 3 (p < 0.0001), and month 6 (p = 0.0094). Fatigue improved significantly at month 3 (p = 0.0073). Other PROs, including morning stiffness, PtGA, disability, work productivity, and activity impairment, also improved. Patients who achieved remission/LDA had significant faster decline in pain, fatigue, PtGA, and work productivity compared to those who did not. Pain was positively correlated with disease activity measures at months 1, 3, and 6, while fatigue was positively associated with disease activity measures at months 3 and 6 only. Morning stiffness, PtGA, and disability correlated with disease activity at months 1 and 3. Conclusions: Patients with RA with MDA/HDA in China experienced significant improvement in pain and fatigue over 6 months. Improvement in DAS28-CRP was associated with faster improvement in certain PROs. While disease activity correlated with some PROs, they did not fully capture patient experience, highlighting the importance of PROs in RA management. © The Author(s) 2025.

引用

页码：2906 / 2921

页数：15

共 43 条

[21]

Curtis J.R., Shan Y., Harrold L., Zhang J., Greenberg J.D., Reed G.W., Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes, Arthritis Care Res (Hoboken), 65, 10, pp. 1707-1712, (2013)

[22]

Wen H., Ralph Schumacher H., Li X., Gu J., Ma L., Wei H., Et al., Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study, Int J Rheum Dis, 15, 4, pp. 380-389, (2012)

[23]

Fautrel B., Alten R., Kirkham B., de la Torre I., Durand F., Barry J., Et al., Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis, Rheumatol Int, 38, 6, pp. 935-947, (2018)

[24]

Gossec L., Dougados M., Rincheval N., Balanescu A., Boumpas D.T., Canadelo S., Et al., Elaboration of the preliminary rheumatoid arthritis impact of disease (RAID) score: a EULAR initiative, Ann Rheum Dis, 68, 11, pp. 1680-1685, (2009)

[25]

van Tuyl L.H.D., Sadlonova M., Hewlett S., Davis B., Flurey C., Goel N., Et al., The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission, Ann Rheum Dis, 76, 5, pp. 855-861, (2017)

[26]

Kay J., Upchurch K.S., ACR/EULAR 2010 rheumatoid arthritis classification criteria, Rheumatology (Oxford), 51, pp. vi5-vi9, (2012)

[27]

Yu C., Li M., Duan X., Fang Y., Li Q., Wu R., Et al., Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis, Clin Exp Rheumatol, 36, 5, pp. 836-840, (2018)

[28]

Singh J.A., Saag K.G., Bridges S.L., Akl E.A., Bannuru R.R., Sullivan M.C., Et al., 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis, Arthritis Care Res, 68, 1, pp. 1-25, (2016)

[29]

Weman L., Salo H., Kuusalo L., Huhtakangas J., Vahasalo P., Backstrom M., Et al., Disease burden measured by patient-reported outcomes: does psoriatic arthritis feel worse than rheumatoid arthritis? A cross-sectional nationwide study, Clin Exp Rheumatol, 41, 11, pp. 2177-2181, (2023)

[30]

Michelsen B., Fiane R., Diamantopoulos A.P., Soldal D.M., Hansen I.J.W., Sokka T., Et al., A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, PLoS ONE, 10, 4, (2015)

← 1 2 3 4 5 →